Intralesional injection versus mouth rinse of triamcinolone acetonide in oral lichen planus: A randomized controlled study

Otolaryngology - Head and Neck Surgery (United States)

Volumn 148, Issue 3, 2013, Pages 443-449

  Lee, Young Chan ^a   Shin, Seung Youp ^a   Kim, Sung Wan ^a   Eun, Young Gyu ^a  

^a Kyung Hee University College of Medicine   (South Korea)

Author keywords

Intralesional injection; Lichen planus; Triamcinolone acetonide

Indexed keywords

MOUTHWASH; TRIAMCINOLONE ACETONIDE; ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; CONTROLLED STUDY; CUSHINGOID SYNDROME; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; LICHEN PLANUS; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; ORAL HEALTH IMPACT PROFILE 14; PAIN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; THRUSH; VISUAL ANALOG SCALE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; INTRALESIONAL DRUG ADMINISTRATION; MIDDLE AGED;

ANTI-INFLAMMATORY AGENTS; FEMALE; HUMANS; INJECTIONS, INTRALESIONAL; LICHEN PLANUS, ORAL; MALE; MIDDLE AGED; MOUTHWASHES; TRIAMCINOLONE ACETONIDE;

MLCS; MLOWN;

EID: 84876087588     PISSN: 01945998     EISSN: 10976817     Source Type: Journal    
DOI: 10.1177/0194599812473237     Document Type: Article

References (43)

1. Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thongprasom K. Current controversies in oral lichen planus: report of an international consensus meeting. Part 1. Viral infections and etiopathogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100:40-51. (Pubitemid 40813390)
2. Dissemond J. Oral lichen planus: an overview. J Dermatolog Treat. 2004;15:136-140. (Pubitemid 39214572)
3. Zegarelli D. Multimodality steroid therapy of erosive and ulcerative oral lichen planus. J Oral Med. 1983;38:127.
4. Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C. Potential hazards of topical steroid therapy. Am J Dis Child. 1983;137:1130-1131.
5. Passeron T, Lacour JP, Fontas E, Ortonne JP. Treatment of oral erosive lichen planus with 1% pimecrolimus cream: a double-blind, randomized, prospective trial with measurement of pimecrolimus levels in the blood. Arch Dermatol. 2007;143:472.
6. Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thongprasom K. Current controversies in oral lichen planus: report of an international consensus meeting. Part 2. Clinical management and malignant transformation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100:164-178. (Pubitemid 41020782)
7. Scott J, Huskisson E. Graphic representation of pain. Pain. 1976;2:175-184.
8. Slade GD. Derivation and validation of a short-form oral health impact profile. Community Dent Oral Epidemiol. 1997; 25:284-290. (Pubitemid 127533991)
9. Slade GD, Nuttall N, Sanders AE, Steele JG, Allen PF, Lahti S. Impacts of oral disorders in the United Kingdom and Australia. Br Dent J. 2005;198:489-493. (Pubitemid 40627473)
10. Escudier M, Ahmed N, Shirlaw P, et al. A scoring system for mucosal disease severity with special reference to oral lichen planus. Br J Dermatol. 2007;157:765-770. (Pubitemid 47389892)
11. Zhao Z, Savage N, Sugerman P, et al. Mast cell/T cell interactions in oral lichen planus. J Oral Pathol Med. 2002;31: 189-195. (Pubitemid 34458417)
12. Kawamura E, Nakamura S, Sasaki M, et al. Accumulation of oligoclonal T cells in the infiltrating lymphocytes in oral lichen planus. J Oral Pathol Med. 2003;32:282-289. (Pubitemid 36565646)
13. Dorrego MV, Correnti M, Delgado R, Tapia FJ. Oral lichen planus: immunohistology of mucosal lesions. J Oral Pathol Med. 2002;31:410-414. (Pubitemid 34973688)
14. Thongprasom K, Dhanuthai K, Sarideechaigul W, Chaiyarit P, Chaimusig M. Expression of TNF-α in oral lichen planus treated with fluocinolone acetonide 0.1%. J Oral Pathol Med. 2006;35:161-166.
15. Eisenberg E. Oral lichen planus: a benign lesion. J Oral Maxillofac Surg. 2000;58:1278-1285.
16. Kumar S, Singh RJ, Reed AM, Lteif AN. Cushing's syndrome after intra-articular and intradermal administration of triamcinolone acetonide in three pediatric patients. Pediatrics. 2004; 113:1820-1824. (Pubitemid 38698002)
17. Jeal W, Faulds D. Triamcinolone acetonide: a review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis. Drugs. 1997;53:257.
18. Khanna J, Andrade N. Oral submucous fibrosis: a new concept in surgical management: report of 100 cases. Int J Oral Maxillofac Surg. 1995;24:433-439.
19. Lai D, Chen H, Lin L, Huang YL, Tsai CC. Clinical evaluation of different treatment methods for oral submucous fibrosis: a 10-year experience with 150 cases. J Oral Pathol Med. 1995;24:402-406.
20. Kermer C, Millesi W, Watzke I. Local injection of corticosteroids for central giant cell granuloma: a case report. Int J Oral Maxillofac Surg. 1994;23:366-368. (Pubitemid 124012692)
21. Haddad IK. Temporomandibular joint osteoarthrosis. Saudi Med J. 2000;21:675-679.
22. Rajeevan N, Soumithran C. Intralesional corticosteroid injection for central giant cell granuloma: a case report. Int J Oral Maxillofac Surg. 1998;27:303-304. (Pubitemid 128364307)
23. Kurtz M, Mesa M, Alberto P. Treatment of a central giant cell lesion of the mandible with intralesional glucocorticosteroids. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;91: 636-637. (Pubitemid 33601675)
24. Xia J, Li C, Hong Y, Yang L, Huang Y, Cheng B. Short-term clinical evaluation of intralesional triamcinolone acetonide injection for ulcerative oral lichen planus. J Oral Pathol Med. 2006;35:327-331. (Pubitemid 43876215)
25. Xiong C, Li Q, Lin M, et al. The efficacy of topical intralesional BCG-PSN injection in the treatment of erosive oral lichen planus: a randomized controlled trial. J Oral Pathol Med. 2009;38:551-558.
26. Farhi D, Dupin N. Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: facts and controversies. Clin Dermatol. 2010;28:100-108.
27. Ungphaiboon S, Nittayananta W, Vuddhakul V, et al. Formulation and efficacy of triamcinolone acetonide mouthwash for treating oral lichen planus. Am J Health Syst Pharm. 2005;62:485-491. (Pubitemid 40332258)
28. Rhodus N, Cheng B, Bowles W, Myers S, Miller L, Ondrey F. Proinflammatory cytokine levels in saliva before and after treatment of (erosive) oral lichen planus with dexamethasone. Oral Dis. 2006;12:112-116.
29. Hegarty A, McGrath C, Hodgson TA, Porter SR. Patientcentred outcome measures in oral medicine: are they valid and reliable? Int J Oral Maxillofac Surg. 2002;31:670-674.
30. González-García A, Diniz-Freitas M, Gándara-Vila P, et al. Triamcinolone acetonide mouth rinses for treatment of erosive oral lichen planus: efficacy and risk of fungal over-infection. Oral Dis. 2006;12:559-565. (Pubitemid 44624359)
31. Rödström P, Hakeberg M, Jontell M, Nordin P. Erosive oral lichen planus treated with clobetasol propionate and triamcinolone acetonide in Orabase: a double-blind clinical trial. J Dermatolog Treat. 1994;5:7-10. (Pubitemid 24105382)
32. Hegarty AM, Hodgson TA, Lewsey JD, Porter SR. Fluticasone propionate spray and betamethasone sodium phosphate mouthrinse: a randomized crossover study for the treatment of symptomatic oral lichen planus. J Am Acad Dermatol. 2002; 47:271-279.
33. Ghabanchi J, Najafi RB, Haghnegahdar S. Treatment of oral inflammatory diseases with a new mucoadhesive prednisolone tablet versus triamcinolone acetonide paste. Iran Red Crescent Med J. 2009;11:155-159.
34. Carbone M, Arduino P, Carrozzo M, et al. Topical clobetasol in the treatment of atrophic-erosive oral lichen planus: a randomized controlled trial to compare two preparations with different concentrations. J Oral Pathol Med. 2009;38:227-233.
35. Campisi G, Giandalia G, De Caro V, Di Liberto C, Aricò P, Giannola LI. A new delivery system of clobetasol-17-propionate (lipid-loaded microspheres 0.025%) compared with a conventional formulation (lipophilic ointment in a hydrophilic phase 0.025%) in topical treatment of atrophic/erosive oral lichen planus: a phase IV, randomized, observer-blinded, parallel group clinical trial. Br J Dermatol. 2004;150:984-990. (Pubitemid 38903533)
36. Levin C, Maibach HI. Topical corticosteroid-induced adrenocortical insufficiency: clinical implications. Am J Clin Dermatol. 2002;3:141-147. (Pubitemid 34533774)
37. Gilbertson EO, Spellman MC, Piacquadio DJ, Mulford MI. Super potent topical corticosteroid use associated with adrenal suppression: clinical considerations. J Am Acad Dermatol. 1998;38:318-321. (Pubitemid 28115240)
38. Thongprasom K, Luangjarmekorn L, Sererat T, Taweesap W. Relative efficacy of fluocinolone acetonide compared with triamcinolone acetonide in treatment of oral lichen planus. J Oral Pathol Med. 1992;21:456-458.
39. Lozada-Nur F, Miranda C, Maliksi R. Double-blind clinical trial of 0.05% clobetasol proprionate ointment in orabase and 0.05% fluocinonide ointment in orabase in the treatment of patients with oral vesiculoerosive diseases. Oral Surg Oral Med Oral Pathol. 1994;77:598-604.
40. Gonzalez-Moles MA, Morales P, Rodriguez-Archilla A, Isabel IR, Gonzalez-Moles S. Treatment of severe chronic oral erosive lesions with clobetasol propionate in aqueous solution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;93: 264-270. (Pubitemid 41124681)
41. Cribier B, Frances C, Chosidow O. Treatment of lichen planus: an evidence-based medicine analysis of efficacy. Arch Dermatol. 1998;134:1521.
42. Cawson R. Treatment of oral lichen planus with betamethasone. BMJ. 1968;1:86-89.
43. Locker D, Jokovic A, Clarke M. Assessing the responsiveness of measures of oral health-related quality of life. Community Dent Oral Epidemiol. 2004;32:10-18. (Pubitemid 41724468)